Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 13/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.54 |
| ▸ | CTRL | P40313 | 1/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.53 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.53 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.53 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.53 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.53 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.53 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.53 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.53 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.53 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.53 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.53 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24360679 | 0.98 | OPRK1 (0.62) | OPRK1OPRM1TMPRSS11DCTRLPSMB5 | |
| SCHEMBL20363358 | 0.94 | OPRK1 (0.73) | OPRK1OPRM1 | |
| SCHEMBL11927488 | 0.92 | OPRK1 (0.69) | OPRK1OPRM1 | |
| SCHEMBL24001142 | 0.92 | OPRK1 (0.65) | OPRK1TMPRSS11DCTRLPSMB5PSMB9 | |
| SCHEMBL24360600 | 0.92 | OPRK1 (0.63) | OPRK1TMPRSS11DCTRLPSMB5PSMB9 | |
| SCHEMBL22961917 | 0.90 | OPRK1 (0.77) | OPRK1OPRM1 | |
| SCHEMBL21233391 | 0.90 | OPRK1 (0.62) | OPRK1OPRM1TMPRSS11DCTRLPSMB5 | |
| SCHEMBL10301405 | 0.89 | OPRK1 (0.73) | OPRK1OPRM1 | |
| SCHEMBL21886316 | 0.88 | OPRK1 (0.66) | OPRK1OPRM1 | |
| SCHEMBL20363365 | 0.87 | OPRK1 (0.75) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885TMPRSS11D 2519/4885 |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885TMPRSS11D 2519/4885 |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885TMPRSS11D 2519/4885 |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885TMPRSS11D 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.